During the six months ended 30 September 2025, Aceso Life Science Group (00474) recorded revenue of HK$29 million from continuing operations, compared with HK$23 million in the same period last year. The group recognized a profit of HK$386 million from continuing operations, mainly driven by a gain on the disposal of a subsidiary that amounted to HK$801 million, offset in part by a HK$317 million loss from the disposal of an associate. Overall profit attributable to owners was HK$386 million, compared to a loss of HK$137 million in the same period last year.

Following the disposal of its subsidiary, the group no longer consolidates that subsidiary’s diversified businesses, which included financial services and construction-related operations. As a result, the group now focuses primarily on its property leasing segment, centered around a commercial building located in Central London. The property’s revenue increase was supported by fewer rent-free periods granted this year and stable demand from reputable international tenants.

Finance costs declined to HK$41 million due to partial repayment of bank and other borrowings. Meanwhile, administrative expenses rose to HK$55 million, mostly attributable to legal and professional fees incurred in the group’s UK property refinancing agreement completed in September 2025. Cash and cash equivalents and pledged bank deposits stood at HK$187 million.

Management indicates that the group aims to enhance the property’s long-term rental value through planned upgrades and refurbishments, anticipating continued demand in Central London’s commercial leasing market. No interim dividend was declared for the period.